Table 2.
Stratification of Patients in the impEF Group by the Median BNP Level at 6 Months After CRT Implantation
| Low BNP group (n=51) |
High BNP group (n=51) |
P value | |
|---|---|---|---|
| Age (years) | 64±14 | 69±14 | 0.041 |
| Body mass index (kg/m2) | 24±4 | 23±4 | 0.219 |
| Male sex | 36 (71) | 28 (55) | 0.151 |
| Hypertension | 24 (47) | 28 (55) | 0.553 |
| Diabetes | 11 (22) | 15 (29) | 0.496 |
| CKD | 12 (24) | 23 (45) | 0.036 |
| Atrial fibrillation | 25 (49) | 29 (57) | 0.552 |
| ICM | 3 (6) | 14 (27) | 0.007 |
| DCM | 25 (49) | 11 (22) | 0.007 |
| HCM | 1 (2) | 10 (20) | 0.008 |
| Sarcoidosis | 7 (14) | 11 (22) | 0.436 |
| Secondary prevention | 10 (20) | 8 (16) | 0.796 |
| LBBB | 21 (41) | 12 (24) | 0.090 |
| QRS duration (ms) | 171 [149–186] | 159 [143–179] | 0.298 |
| Medication | |||
| β-blocker | 38 (75) | 36 (71) | 0.825 |
| ACE inhibitor or ARB | 38 (75) | 43 (84) | 0.328 |
| MRA | 28 (55) | 26 (51) | 0.843 |
| Amiodarone | 7 (14) | 13 (25) | 0.212 |
| Baseline LVEF (%) | 30 [23–35] | 33 [30–37] | 0.024 |
| Baseline BNP (pg/mL) | 134 [64–189] | 266 [197–405] | 0.001 |
| NYHA class II | 41 (80) | 37 (73) | 0.484 |
| NYHA class III | 10 (20) | 14 (27) | 0.484 |
Unless indicated otherwise, data are presented as n (%), mean±SD, or median [interquartile range]. Abbreviations as in Table 1.